NCT06691984 2026-03-06Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)AmgenPhase 3 Recruiting675 enrolled
NCT07213674 2026-02-27A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerAmgenPhase 3 Recruiting750 enrolled